The intravenous route is not FDA approved and is generally not recommended except when no other alternatives are available. Intravenous administration appears to be associated with a higher risk of QT prolongation and torsade de pointes (TdP) than other forms of administration. The manufacturer recommends ECG monitoring for QT prolongation and arrhythmias if IV administration is required. A dose in the range of 1 to 5 mg IV has been suggested, with the dose being repeated at 30 to 60 minute intervals, if needed. A maximum IV dose has not been established. The lowest effective dose should be used in conjunction with conversion to oral therapy as soon as possible.
Let your doctor know if you currently have or have ever been diagnosed with thyroid disease, breast cancer, seizures, liver disease, kidney disease, bipolar issues, an electrolyte imbalance, or heart conditions including long QT (LQTS) syndrome, and chest pain. These conditions may affect your ability to tolerate Haldol. People who have Parkinson's disease should not take Haldol. If you have ever had an extreme reaction or side effect to another medication prescribed to treat mental health issues, relay this information to your doctor. This drug is not recommended for elderly people experiencing dementia or related conditions as it may increase the risk of death.
There are no well controlled studies with HALDOL (haloperidol) in pregnant women. There are reports, however, of cases of limb malformations observed following maternal use of HALDOL along with other drugs which have suspected teratogenic potential during the first trimester of pregnancy. Causal relationships were not established in these cases. Since such experience does not exclude the possibility of fetal damage due to HALDOL, this drug should be used during pregnancy or in women likely to become pregnant only if the benefit clearly justifies a potential risk to the fetus. Infants should not be nursed during drug treatment.